Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) Short Interest Up 84.9% in August

Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 12,218 shares, an increase of 84.9% from the August 15th total of 6,607 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Laboratorios Farmaceuticos Rovi Price Performance

Shares of OTCMKTS LABFF opened at C$67.17 on Wednesday. The business has a 50-day moving average of C$66.42 and a 200-day moving average of C$66.06. Laboratorios Farmaceuticos Rovi has a 12 month low of C$65.86 and a 12 month high of C$67.17.

Laboratorios Farmaceuticos Rovi Company Profile

Laboratorios Farmacéuticos ROVI SA is a Spanish specialty pharmaceutical company focused on the development, manufacturing and commercialization of injectable therapies. The company has built expertise in low-molecular-weight heparins and long-acting injectable antipsychotics, alongside drug-delivery technologies such as prefilled syringes and autoinjector systems. ROVI’s product portfolio spans both originator and biosimilar medicines, targeting therapeutic areas including psychiatry, oncology and cardiology.

ROVI’s core franchise includes established anticoagulant products based on tinzaparin sodium, as well as innovative depot formulations of risperidone developed using its proprietary in situ microparticle (ISM) technology.